Effect of insulin on arsenic toxicity in diabetic rats-liver function studies

Biological Trace Element Research

Volumn 132, Issue 1-3, 2009, Pages 215-226

  Singh, Neetu ^a   Rana, Suresh Vir Singh ^a  

^a CH CHARAN SINGH UNIVERSITY   (India)

Author keywords

Arsenic; Diabetes mellitus; Insulin; Liver; Serum transaminases

Indexed keywords

ALANINE AMINOTRANSFERASE; ALLOXAN; ARSENIC; ARSENIC TRIOXIDE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GLUCOSE 6 PHOSPHATASE; INSULIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARBOHYDRATE METABOLISM; CONTROLLED STUDY; DRUG ACCUMULATION; ENZYME ACTIVITY; HISTOPATHOLOGY; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN TREATMENT; LIVER FUNCTION; MALE; MITOCHONDRIAL RESPIRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT;

ANIMALS; ARSENIC; BILIRUBIN; BLOOD GLUCOSE; GLUCOSE-6-PHOSPHATASE; INSULIN; LIVER; LIVER FUNCTION TESTS; MALE; RATS; RATS, WISTAR; TRANSAMINASES;

RATTUS;

EID: 72449153852     PISSN: 01634984     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12011-009-8396-8     Document Type: Article

References (55)

1. IARC, Overall evaluation of carcinogenicity: an updating of IARC monographs. Vol. 1-42, IARC Monograph, Eval. Carcinog. Risks Hum Supplement. 7 (1987).
2. M Rahman G Wingren O Axelson 1996 Diabetes mellitus among Swedish art glass workers-an effect of arsenic exposure Scand Work Environ Health 22 149 149
3. M Rahman M Tondel IA Chowdhury O Axelson 1999 Relations between exposure to arsenic, skin lesion, and glucosuria Occup Environ Med 56 277 281 10.1136/oem.56.4.277 1:STN:280:DyaK1MznvVOnsg%3D%3D 10450246
4. CH Tseng TY Tai CK Chong CP Tseng MS Lai BJ Lin, et al. 2000 Long term arsenic exposure and incidence of non-insulin dependent diabetes mellitus: a cohort study in arseniasis by perendemic villages in Taiwan Environ Health Perspect 108 847 851 10.2307/3434992 1:CAS:528:DC%2BD3cXntlymtLo%3D 11017889
5. CH Tseng CP Tseng HY Chiou YM Hsuneh CK Chong CJ Chen 2002 Epidemiologic evidence of diabetogenic effect of arsenic Toxicol Lett 133 69 76 10.1016/S0378-4274(02)00085-1 1:CAS:528:DC%2BD38XksFKqsb4%3D 12076511 (Pubitemid 34655544)
6. SL Wang JM Chiau CJ Chen CH Tseng WL Chow CC Wang, et al. 2003 Prevalence of non-insulin dependent diabetes mellitus and related vascular diseases in South Western arseniasis-endemic and non-endemic areas in Taiwan Environ Health Perspect 111 155 159 12573898
7. A Navas-Acien EK Silbergeld RA Streeter JM Clark TA Burke E Guallar 2006 Arsenic exposure and Type 2 diabetes: A systematic review of the experimental and epidemiological evidence Env Health Perspec 114 641 648 1:CAS:528: DC%2BD28XltVWqtrs%3D
8. NRC (National Research Council), Arsenic in drinking water 2001 update. Washington DC. National Academy Press (2001).
9. WHO, United Nations Synthesis Report on arsenic drinking water. Developed on behalf of the United Nations Administrative Committee on cooperation Sub-Committee on water resources with active participation of UNICEF, UNIDO, IAEA and the World Bank. World Health organization available: http://www.who.int/waters-sanitation-health/dwq/arsenic3/en/ [accessed / December 2005] (2001).
10. Aposhian HV (1989) Biochemical toxicologyof arsenic. In: Hodgson E, Bend JR, Philpot RM (eds) reviews in Biochemical toxicology, Vol. 10. Elsevier, Amsterdam, pp. 265-289
11. NRC (National Research Council) (1999) Arsenic in drinking water. National Academy Press, Washington DC
12. EP Kennedy AL Lehninger 1949 Oxidation of fatty acids and tricarboxylic acid cycle intermediates by isolated rat liver mitochondria J Biol Chem 179 957 972 1:CAS:528:DyaH1MXktFGrsw%3D%3D 18150026
13. CH Tseng 2004 The potential biological mechanisms of arsenic-induced diabetes mellitus Toxicol Appl Pharmacol 197 67 83 10.1016/j.taap.2004.02.009 1:CAS:528:DC%2BD2cXkt1ajur4%3D 15163543 (Pubitemid 38639898)
14. YC Chen SY Shiau JK Lin 1998 Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis J Cell Physiol 177 324 333 10.1002/(SICI)1097-4652(199811)177:2<324::AID-JCP14>3.0.CO;2-9 1:CAS:528:DyaK1cXmsVeiur4%3D 9766529 (Pubitemid 28452833)
15. T Allen SVS Rana 2003 Oxidative stress by inorganic arsenic: Modulation by thyroid hormones in rats Comp Biochem Physiol Part C 135 157 162
16. SVS Rana 2008 Metals and apoptosis: Recent developments J Trace Elem Med Biol 22 262 284 10.1016/j.jtemb.2008.08.002 1:CAS:528:DC%2BD1MXhsFSntLo%3D 19013355
17. S Maiti AK Chatterjee 2000 Differential response of cellular antioxidant mechanism of liver and kidney to arsenic exposure and its relation to diatary protein deficiency Environ Toxicol Pharmacol 8 227 235 10.1016/S1382-6689(00) 00046-6 1:CAS:528:DC%2BD3cXmtlKjsbw%3D 10996542 (Pubitemid 30734492)
18. S Singh G Gadhok SVS Rana 2006 Effect of alloxan induced diabetes on liver and kidney function in arsenic treated rats Toxicology and Environmental Chemistry 88 673 682 10.1080/01442350600866936 1:CAS:528:DC%2BD28XhtlCnsbjJ (Pubitemid 44771269)
19. K Chawalit P Stret Argusa A Thitapanda 1982 Comparative effects of diabetogenic agents on hepatic drug metabolism Drug Metab Dispos 10 81 86 1:CAS:528:DyaL38Xhs1Sgurs%3D 6124390
20. PA Longhurst LB Lacagnin DE Staats HD Colby 1986 Changes in hepatic drug metabolism in alloxan diabetic male rabbits Biochem Pharmacol 35 1768 1771 10.1016/0006-2952(86)90341-2 1:CAS:528:DyaL28XktVCms74%3D 3085677 (Pubitemid 16067804)
21. SVS Rana N Rastogi 2002 Antioxidative enzymes in the liver and kidney of diabetic rats and their implications in cadmium toxicity Physiol Chemistry Phys and Med NMR 32 67 74
22. SVS Rana N Rastogi 1998 Effects of cadmium on liver function in diabetic rats Toxicology and Ind Health 14 217 225
23. M Rehman M Tondel SA Ahmad O Axelson 1998 Diabetes mellitus associated with arsenic exposure in Bangladesh Am J Epidemiol 148 198 203
24. S Reitman S Frankel 1957 A colorimetric method for determination of serum glutamic-oxaloacitic and glutamic pyruvic transaminase Am J Clin Pathol 28 56 68 1:CAS:528:DyaG2sXpvFyiuw%3D%3D 13458125
25. Burtis CA, Ashwood ER (1996) Liver function. In: 111 Editor Tietz fundamentals of clinical chemistry philadiphia. W.B. Saunders and Company, pp. 539-568
26. WH Fishman SS Goldman R DeLellis 1967 Dual localization of beta-glucuronidase in endoplasmic reticulum and in lysosomes Nature 213 457 460 10.1038/213457a0 1:CAS:528:DyaF2sXhtVWqtLo%3D 4166303
27. EC Tsai IB Hirsch JD Brunzell A Chait 1994 Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM Diabetes 43 1010 1014 10.2337/diabetes.43.8.1010 1:STN:280:DyaK2czhsVSqsQ%3D%3D 8039594
28. M Kawamura JW Heineckc A Chait 1994 Pathophysiological concentrations of glucose promote oxidative modification of low density lipoprotein by a superoxide-dependent pathway J Clin Invest 94 771 778 10.1172/JCI117396 1:CAS:528:DyaK2cXltlWnt70%3D 8040332
29. O Hori SD Yan S Ogawa K Kuwabara M Matsumoto D Stern AM Schmidt 1996 The receptor for advanced glycation end-products has a central role in mediating the effects o advanced glycation end-products on the development of vascular disease in diabetes mellitus Nephrol Dial Transplant 11 13 16 1:CAS:528:DyaK2sXhsFCitLk%3D 9044300
30. CJ Mullarkey D Edelstein M Brownlee 1990 Free radical generation by early glycation products: A mechanism for accelerated atherogenesis in diabetes Biochem Biophys Res Commun 173 932 939 10.1016/S0006-291X(05)80875-7 1:CAS:528:DyaK3MXlvFykuw%3D%3D 2176495
31. AD McCarthy SB Etcheverry AM Cortizo 2001 Effect of insulin-like growth factor-I and its binding proteins: Role in osteoblast development Acta Diabetol 38 113 122 10.1007/s005920170007 1:CAS:528:DC%2BD38XitVGgtLo%3D 11827431 (Pubitemid 34042074)
32. JW Baynes SR Thorpe 1999 Role of oxidative stress in diabetic complications: A new perspective on an old paradigm Diabetes 48 1 9 10.2337/diabetes.48.1.1 1:CAS:528:DyaK1MXhvV2rtA%3D%3D 9892215 (Pubitemid 29019345)
33. AM El-Hawari GL Plaa 1983 Potentiation of thioacetamide-induced hepatotoxicity in alloxan- and streptozotocin-diabetic rats Toxicol Lett 17 293 300 10.1016/0378-4274(83)90241-2 1:CAS:528:DyaL3sXlsFensrc%3D 6226124
34. GK Hanasono MG Cote GL Plaa 1975 Potentiation of carbon tetrachloride-induced hepatotoxicity in alloxan-or steptozotocin-diabetic rats J Pharmacol Exp Ther 192 592 604 1:CAS:528:DyaE2MXhtF2ksb8%3D 164533
35. SP Sawant AV Dnyanmote K Shankers PB Limaye JR Latendresse HM Mehendale 2004 Potentiation of carbon tetrachloride hepatotoxicity and lethality in type 2 diabetic rats J Pharmacol Exp Ther 308 694 704 10.1124/jpet.103.058834 1:CAS:528:DC%2BD2cXhtlSqu7o%3D 14610242 (Pubitemid 38134233)
36. SP Sawant AV Dnyanmote A Warbritton JR Latendresse HM Mehendale 2006 Type 2 diabetic rats are sensitive to thioacetamide hepatotoxicity Toxicol Appl Pharmacol 211 221 232 10.1016/j.taap.2005.07.019 1:CAS:528:DC%2BD28XisF2ju7c%3D 16153671
37. K Yamanaka S Okada 1994 Induction of lung-specific DNA damage by metabolically methylated arsenics via the production of free radicals Environ. Health Perspect. 102 37 40 10.2307/3431760 1:CAS:528:DyaK2cXmvFCrs7s%3D 7843134 (Pubitemid 24316356)
38. J Liu Y Liu RA Goyer W Achanzar MP Waalker 2000 Metallothionein-I/II null mice are more sensitive than wild-type mice to the hepatotoxic and nephrotoxic effects of chronic oral or injected arsenicals Toxicol Sci 55 460 467 10.1093/toxsci/55.2.460 1:CAS:528:DC%2BD3cXjsl2qsbg%3D 10828279
39. HV Aposhian 1997 Enzymatic methylation of arsenic species and other new approaches to As toxicity Annual review pharmacology and Toxicology 37 397 419 10.1146/annurev.pharmtox.37.1.397 1:STN:280:DyaK2s3nslyrsQ%3D%3D
40. MP Waalkes LK Keefer BA Diwan 2000 Induction of proliferative lesions of the uterus, testes and liver in Swiss mice given repreated injections sodium arsenite: Possible estrogenic mode of action Toxicol Appl Pharmacol 166 24 35 10.1006/taap.2000.8963 1:CAS:528:DC%2BD3cXktlSnurg%3D 10873715 (Pubitemid 30470616)
41. JE Bodwell LA Engsley JW Hamilton 2004 Arsenic at very low concentrations alters glucocorticoid receptor (GR) mediated gene activation but not GR-mediated gene repression: complex dose-response effects are closely correlated with levels of activated GR and require a functional GR DNA binding domain Chem Res Toxicol 17 1064 1076 10.1021/tx0499113 1:CAS:528: DC%2BD2cXls1Kqtb0%3D 15310238 (Pubitemid 39115330)
42. LM Watts VP Manchem TA Leedom AL Rivard RA McKay D Boo, et al. 2005 Reduction of hepatic and adipose tissue glucocorticoid receptor expression with antisense oligonueleotides improves hyperglycemia and hyperlipidemia in diabetic rodents without causing systemic glucorticoid antagonism Diabetes 54 1846 1853 10.2337/diabetes.54.6.1846 1:CAS:528:DC%2BD2MXltVaitLo%3D 15919808 (Pubitemid 40770776)
43. DS Paul AW Harmon V Devesa DJ Thomas M Stybol 2007 Molecular mechanisms of the diabetogenic effects of arsenic: inhibition of insulin signaling by arsenite and methylarsonous acid Environ Hlth Perspect 115 734 742 1:CAS:528:DC%2BD2sXmt1Sksbw%3D
44. MR Past DE Cook 1982 Effects of diabetes on rat lvier cytochrome P450 evidence for a unique diabetes dependent rat liver CYP450 Biochem Pharmacol 31 3329 3334 10.1016/0006-2952(82)90569-X 1:CAS:528:DyaL38XlvFKmsL4%3D 7150359 (Pubitemid 12031275)
45. MF Hughes M Menache DJ Thompson 1994 Dose-dependent disposition of sodium arsenate in mice following acute oral exposure Fundam Appl Toxicol 22 80 89 10.1006/faat.1994.1011 1:CAS:528:DyaK2cXhsFKiurw%3D 8125217 (Pubitemid 24073660)
46. I Csanaky B Nemeti Z Gregus 2003 Dose-dependent bio-transformation of arsenite in rats-not S-adenosyl methionine depletion impairs arsenic methylation at high dose Toxicology 183 77 91 10.1016/S0300-483X(02)00444-4 1:CAS:528:DC%2BD38XpslSjsbg%3D 12504344 (Pubitemid 36005391)
47. BA Fowler JS Woods CM Schiller 1977 Ultrastructural and biochemical effects of prolonged oral arsenic exposure on liver mitochondria of rats Environ Health Persp 19 197 204 10.2307/3428475 1:CAS:528:DyaE1cXhs1OktQ%3D%3D
48. IARC, Evaluation of carcinogenic risks to humans: some Drinking-water Disinfectants and Contaminants, including Arsenic. Volume 84, Lyon: International Agency for Research on Cancer 512p (2004).
49. Tabershan IR, Utidjian HMB, Kawahara B (1977) Chemical hazards, "Occupational disease: A guide to their recognition." USDHEW, NIOH Publication, Washington DC, pp. 77-181
50. M Franklin WB Been RC Hardin 1950 Fowler's solution as an etiologic agent in cirrhosis Am J Med Sci 219 589 596 10.1097/00000441-195006000-00001 1:STN:280:DyaG3c%2FivVyjsA%3D%3D 15419170
51. Klatskin G (1956) Toxic hepatitis. In: Schiff L (ed) "Diseases of the Liver." Lippincott, Philadelphia Pennsylvania, pp. 328-394
52. Schmidt R (1961) Veranderung der dernvolumia und. die bildung von riesenzell-kernan in derleber der weissen maus nach parenteralen alloxangaben. Z Mikoskop-Anast Forsch 67:233-252
53. A Albores ME Cebrian PH Bach JC Connelly RH Ninton JW Bridges 1989 Sodium arsenite induced alterations in bilirubin excretion and heme metabolism J Biochem Toxicol 4 1 6 10.1002/jbt.2570040202
54. CM Schiller R Walden BA Fowler 1981 Interaction between arsenic and alloxan-induced diabetes-effects on rat urinary enzyme levels Biochem Pharmacol 30 168 170 10.1016/0006-2952(81)90189-1 1:CAS:528:DyaL3MXitVegtbY%3D 7236306 (Pubitemid 11210846)
55. A Díaz-Villaseñor MC Sánchez-Soto ME Cebrián P Ostrosky-Wegman M Hiriart 2006 Sodium arsenite impairs insulin secretion and transcription in pancreatic beta-cells Toxicol Appl Pharmacol. 214 30 34 10.1016/j.taap.2005.11.015 16413591 (Pubitemid 43870369)